Advances in biomaterials and regenerative medicine for primary ovarian insufficiency therapy
Source abstract
Abstract
Primary ovarian insufficiency (POI) is an ovarian dysfunction that affects more than 1 % of women and is characterized by hormone imbalances that afflict women before the age of 40. The typical perimenopausal symptoms result from abnormal levels of sex hormones, especially estrogen. The most prevalent treatment is hormone replacement therapy (HRT), which can relieve symptoms and improve quality of life. However, HRT cannot restore ovarian functions, including secretion, ovulation, and fertility. Recently, as part of a developing field of regenerative medicine, stem cell therapy has been proposed for the treatment of POI. Thus, we recapitulate the literature focusing on the use of stem cells and biomaterials for POI treatment, and sum up the underlying mechanisms of action. A thorough understanding of the work already done can aid in the development of guidelines for future translational applications and clinical trials that aim to cure POI by using regenerative medicine and biomedical engineering strategies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Reproductive Biology and Fertility · Tissue Engineering and Regenerative Medicine · Pluripotent Stem Cells Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. ESHRE Guideline: management of women with premature ovarian insufficiency10.1093/humrep/dew027 ↗
2. Impact of premature ovarian failure on mortality and morbidity among Chinese women
3. Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age10.1093/humrep/des356 ↗
4. Age at menopause, cause-specific mortality and total life expectancy10.1097/01.ede.0000165392.35273.d4 ↗
5. Incidence of premature ovarian failure
6. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis
7. casper · 2011
8. Psychosocial vulnerability, resilience resources, and coping with infertility: a longitudinal model of adjustment to primary ovarian insufficiency10.1007/s12160-015-9750-z ↗
9. Yen · 2001
10. Primary ovarian insufficiency10.1016/S0140-6736(10)60355-8 ↗
11. Clinical practice. Primary ovarian insufficiency10.1056/NEJMcp0808697 ↗
12. Niacin inhibits apoptosis and rescues premature ovarian failure10.1159/000495051 ↗
13. Ginsenoside Rg1 improves fertility and reduces ovarian pathological damages in premature ovarian failure model of mice10.1177/1535370217693323 ↗
14. Nitric oxide-induced activation of the type 1 ryanodine receptor is critical for epileptic seizure-induced neuronal cell death10.1016/j.ebiom.2016.08.020 ↗
15. Synergistic effect of melatonin and ghrelin in preventing cisplatin-induced ovarian damage via regulation of FOXO3a phosphorylation and binding to thep27Kip1promoter in primordial follicles10.1111/jpi.12432 ↗
16. Treatment potential of bone marrow-derived stem cells in women with diminished ovarian reserves and premature ovarian failure10.1097/GCO.0000000000000531 ↗
17. Current approaches for the treatment of premature ovarian failure with stem cell therapy10.1016/j.biopha.2018.03.056 ↗
18. The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure10.1186/s13287-018-1008-9 ↗
19. Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis10.1093/jnci/djx166 ↗
20. Concise review: is cardiac cell therapy dead? Embarrassing trial outcomes and new directions for the future10.1002/sctm.17-0196 ↗
21. Advances in the molecular pathophysiology, genetics, and treatment of primary ovarian insufficiency10.1016/j.tem.2018.03.010 ↗
22. The development of fibroblast colonies in monolayer cultures of Guinea-pig bone marrow and spleen cells
23. Mesenchymal stem cells: the past, the present, the future10.1177/1947603509354992 ↗
24. Stem cells in the umbilical cord10.1007/s12015-006-0022-y ↗
25. Mesenchymal stem cell/red blood cell-inspired nanoparticle therapy in mice with carbon tetrachloride-induced acute liver failure10.1021/acsnano.8b00553 ↗
26. Adult mesenchymal stem cells and women's health10.1097/GME.0000000000000408 ↗
27. Adult mesenchymal stem cells: when, where, and how
28. Mesenchymal stem cells: revisiting history, concepts, and assays10.1016/j.stem.2008.03.002 ↗
29. Multilineage potential of adult human mesenchymal stem cells10.1126/science.284.5411.143 ↗
30. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche10.1038/nature09262 ↗
31. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study10.1016/S0140-6736(08)60690-X ↗
32. Mesenchymal stem cells as cellular immunosuppressants10.1016/S0140-6736(08)60666-2 ↗
33. Some morphological and functional characteristics of cells of the porcine theca interna in tissue culture10.1095/biolreprod19.4.712 ↗
34. Restoring ovarian function with human placenta-derived mesenchymal stem cells in autoimmune-induced premature ovarian failure mice mediated by Treg cells and associated cytokines10.1177/1933719117732156 ↗
35. Effects of hPMSCs on granulosa cell apoptosis and AMH expression and their role in the restoration of ovary function in premature ovarian failure mice10.1186/s13287-017-0745-5 ↗
36. Molecular aspects and clinical relevance of GDF9 and BMP15 in ovarian function10.1016/bs.vh.2017.12.003 ↗
37. Cyclophosphamide promotes the proliferation inhibition of mouse ovarian granulosa cells and premature ovarian failure by activating the lncRNA-Meg3-p53-p66Shc pathway10.1016/j.gene.2016.10.011 ↗
38. Granulosa cell and oocyte mitochondrial abnormalities in a mouse model of fragile X primary ovarian insufficiency10.1093/molehr/gaw023 ↗
39. Overexpression of miR-21 in stem cells improves ovarian structure and function in rats with chemotherapy-induced ovarian damage by targeting PDCD4 and PTEN to inhibit granulosa cell apoptosis10.1186/s13287-017-0641-z ↗
40. The therapeutic potential of umbilical cord mesenchymal stem cells in mice premature ovarian failure10.1155/2013/690491 ↗
41. Endometrial mesenchymal stem cells isolated from menstrual blood repaired epirubicin-induced damage to human ovarian granulosa cells by inhibiting the expression of Gadd45b in cell cycle pathway10.1186/s13287-018-1101-0 ↗
42. Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT110.1186/s13287-019-1490-8 ↗
43. HucMSC-derived exosomes mitigate the age-related retardation of fertility in female mice10.1016/j.ymthe.2020.02.003 ↗
44. Stem-cell-based embryo models for fundamental research and translation
45. Umbilical cord blood mesenchymal stem cells as an infertility treatment for chemotherapy induced premature ovarian insufficiency10.3390/biomedicines7010007 ↗
46. The effects of human menstrual blood stem cells-derived granulosa cells on ovarian follicle formation in a rat model of premature ovarian failure10.1002/jemt.23120 ↗
47. Human mesenchymal stem cells partially reverse infertility in chemotherapy-induced ovarian failure10.1177/1933719117699705 ↗
48. Mechanism of resveratrol in improving ovarian function in a rat model of premature ovarian insufficiency10.1111/jog.13680 ↗
49. Upregulation of FSHR and PCNA by administration of coenzyme Q10 on cyclophosphamide-induced premature ovarian failure in a mouse model10.1002/jbt.22398 ↗
50. Heat shock pretreatment of mesenchymal stem cells for inhibiting the apoptosis of ovarian granulosa cells enhanced the repair effect on chemotherapy-induced premature ovarian failure10.1186/s13287-018-0964-4 ↗
51. Effect of transcutaneous electrical acupoint stimulation on protecting against radiotherapy- induced ovarian damage in mice10.1186/s13048-019-0541-1 ↗
52. The protective effect of N-acetylcysteine on ionizing radiation induced ovarian failure and loss of ovarian reserve in female mouse10.1155/2017/4176170 ↗
53. Induced premature ovarian insufficiency by using D galactose and its effects on reproductive profiles in small laboratory animals: a systematic review10.1186/s13048-019-0565-6 ↗
54. NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression10.1126/science.1099755 ↗
55. Wdr62 is involved in female meiotic initiation via activating JNK signaling and associated with POI in humans10.1371/journal.pgen.1007463 ↗
56. Exome sequencing reveals the POLR3H gene as a novel cause of primary ovarian insufficiency10.1210/jc.2018-02485 ↗
57. Fertility rescue and ovarian follicle growth promotion by bone marrow stem cell infusion10.1016/j.fertnstert.2018.01.004 ↗
58. Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice10.1186/s13287-016-0458-1 ↗
59. Human umbilical cord mesenchymal stem cell transplantation restores damaged ovaries10.1111/jcmm.12571 ↗
60. Transplantation of adipose-derived stem cells combined with collagen scaffolds restores ovarian function in a rat model of premature ovarian insufficiency10.1093/humrep/dew041 ↗
61. Human endometrial mesenchymal stem cells restore ovarian function through improving the renewal of germline stem cells in a mouse model of premature ovarian failure10.1186/s12967-015-0516-y ↗
62. Human umbilical cord mesenchymal stem cells therapy in cyclophosphamide-induced premature ovarian failure rat model10.1155/2016/2517514 ↗
63. Transplantation of human menstrual blood stem cells to treat premature ovarian failure in mouse model10.1089/scd.2013.0371 ↗
64. Adipose-derived stem cells improved mouse ovary function after chemotherapy-induced ovary failure10.1186/scrt231 ↗
65. Transplantation of adipose-derived stem cells combined with collagen scaffolds restores ovarian function in a rat model of premature ovarian insufficiency10.1093/humrep/dew041 ↗
66. Fragile X premutation RNA is sufficient to cause primary ovarian insufficiency in mice10.1093/hmg/dds348 ↗
67. hPMSC transplantation restoring ovarian function in premature ovarian failure mice is associated with change of Th17/Tc17 and Th17/Treg cell ratios through the PI3K/Akt signal pathway10.1186/s13287-018-0772-x ↗
68. MicroRNA-21 promotes bone mesenchymal stem cells migration in vitro by activating PI3K/Akt/MMPs pathway10.1016/j.jocn.2017.07.040 ↗
69. Yin · Stem Cell Res. Ther. · 2020 · 11
70. Human placenta‐derived mesenchymal stem cells inhibit apoptosis of granulosa cells induced by IRE1α pathway in autoimmune POF mice10.1002/cbin.11165 ↗
71. Exosomes derived from human adipose mesenchymal stem cells improve ovary function of premature ovarian insufficiency by targeting SMAD10.1186/s13287-018-0953-7 ↗
72. hUMSCs regulate the differentiation of ovarian stromal cells via TGF-beta1/Smad3 signaling pathway to inhibit ovarian fibrosis to repair ovarian function in POI rats10.1186/s13287-020-01904-3 ↗
73. hUMSC transplantation restores ovarian function in POI rats by inhibiting autophagy of theca-interstitial cells via the AMPK/mTOR signaling pathway10.1186/s13287-020-01784-7 ↗
74. Ovarian dysfunction and gene-expressed characteristics of female mice caused by long-term exposure to titanium dioxide nanoparticles10.1016/j.jhazmat.2012.08.049 ↗
75. Tumor necrosis factor-alpha promoter polymorphisms are associated with idiopathic primary ovarian insufficiency in Korean women10.1016/j.fertnstert.2012.07.1111 ↗
76. Single-cell transcriptomic atlas of primate ovarian aging10.1016/j.cell.2020.01.009 ↗
77. Overexpression of miR-21 in stem cells improves ovarian structure and function in rats with chemotherapy-induced ovarian damage by targeting PDCD4 and PTEN to inhibit granulosa cell apoptosis10.1186/s13287-017-0641-z ↗
78. Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits10.1016/j.jcyt.2012.08.001 ↗
79. Mesenchymal stem cells enhance angiogenesis and follicle survival in human cryopreserved ovarian cortex transplantation10.3727/096368914X685267 ↗
80. Bone marrow mesenchymal stem cell transplantation improves ovarian function and structure in rats with chemotherapy-induced ovarian damage10.1080/14653240802035926 ↗
81. Protective effect of vascular endothelial growth factor (VEGF) in frozen-thawed granulosa cells is mediated by inhibition of apoptosis10.1016/j.ejogrb.2005.10.027 ↗
82. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms10.1161/01.RES.0000118601.37875.AC ↗
83. Human primary co-culture angiogenesis assay reveals additive stimulation and different angiogenic properties of VEGF and HGF10.1016/j.cyto.2004.03.003 ↗
84. G-CSF-mobilized peripheral blood mononuclear cells combined with platelet-rich plasma accelerate restoration of ovarian function in cyclophosphamide-induced POI ratsdagger10.1093/biolre/ioz077 ↗
85. Interferon-γ mediates the immunosuppression of bone marrow mesenchymal stem cells on T-lymphocytes in vitro10.1080/10245332.2017.1333245 ↗
86. Human amniotic epithelial cells inhibit granulosa cell apoptosis induced by chemotherapy and restore the fertility10.1186/s13287-015-0148-4 ↗
87. microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential10.1172/JCI123135 ↗
88. Effect of transplantation of bone marrow stromal cell- conditioned medium on ovarian function, morphology and cell death in cyclophosphamide-treated rats
89. Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism10.1186/s13287-017-0514-5 ↗
90. Exosomes derived from human umbilical cord mesenchymal stem cells protect against cisplatin-induced ovarian granulosa cell stress and apoptosis in vitro10.1038/s41598-017-02786-x ↗
91. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy
92. Dose-dependent functional benefit of human cardiosphere transplantation in mice with acute myocardial infarction10.1111/j.1582-4934.2011.01512.x ↗
93. Bioengineered cardiac patch scaffolds
94. Recent advances in biomaterials for 3D scaffolds: a review
95. Cell and biomaterial-based approaches to uterus regeneration10.1093/rb/rbz021 ↗
96. Natural origin biodegradable systems in tissue engineering and regenerative medicine: present status and some moving trends10.1098/rsif.2007.0220 ↗
97. Constructing biomimetic cardiac tissues: a review of scaffold materials for engineering cardiac patches10.1007/s42247-019-00046-4 ↗
98. Premature ovarian failure and tissue engineering10.1002/jcp.29376 ↗
99. Micro and Nanofabrication methods to control cell-substrate interactions and cell behavior: a review from the tissue engineering perspective
100. Corrigendum to: cardiovascular disease in Europe: epidemiological update 201610.1093/eurheartj/ehy342 ↗